

Advisory Committee on the Medical Uses of Isotopes's Report on $^{137}\text{CsCl}$ Irradiators

Summary

After studying the issues, the Advisory Committee on the Medical Uses of Isotopes (ACMUI) came to the following conclusions:

1. Irradiators are necessary for medical practice and medical research.
2. It is not clear from the available data that x-ray sources are biologically equivalent to $^{137}\text{CsCl}$ irradiators.
3. Alternatives to the $^{137}\text{CsCl}$ irradiators currently in operation present greatly increased expense to programs that need the functionality and operational reliability of the irradiators.
4. The recommendation of the National Research Council (NRC) of the National Academies to eliminate the use of irradiators that employ $^{137}\text{CsCl}$ was based on the situation at the time of their study. Since that time, security of medical irradiators units has been substantially strengthened in three ways:
 - a. Increased security of persons with access. The December 2005 NRC orders increased the security requirements for all persons having unescorted access to $^{137}\text{CsCl}$ irradiators, including background checks, personal reference checks, and fingerprinting checks against the FBI fingerprint database.
 - b. Increased security of the facilities housing the units, including high-security locks on facility door, multiple doors with locks for access, motion sensors, video cameras monitored by facility security, preplanning with local law enforcement, database encryption, and secured facility schematics, and drawings.
 - c. Increased security of the units themselves, including locks on source access panels and entry points.

Given these changes, we found that the National Research Council concerns do not currently apply as previously stated, and have been superseded by increased safeguards as required by the Nuclear Regulatory Commission and state regulatory authorities. Well-secured $^{137}\text{CsCl}$ irradiators present little security hazard.

Practicality of Alternatives to $^{137}\text{CsCl}$ Self-Shielded Irradiators*

Blood and Blood-Product Irradiation

Based on our survey of the literature and other publicly available information sources, the only medical x-ray irradiator that the U.S. Food and Drug Administration (FDA) has cleared to irradiate blood and blood products to prevent graft-versus-host disease is the

* Content taken from manuscript submitted to *Health Physics* June 17, 2008: Dodd, B and Vetter, R. "Replacement of ^{137}Cs Irradiators with X-Ray Irradiators"

1 Raycell (Best Theratronics 2008) originally manufactured and sold by Rad Source (Rad
2 Source 2007a) as the unit model RS 3000. Other manufacturers may also be developing
3 plans for new irradiators.

4 The first question regarding practicality of an x-ray machine to irradiate blood or
5 blood products is whether there are any technical issues. Although the photon energy of
6 x-ray machines is lower than those of ^{137}Cs , Janatpour et al. (2005) demonstrated that x-
7 ray machines can deliver the necessary 25 Gy dose with sufficient uniformity and
8 stability to meet FDA guidelines. The typical x-ray irradiator generates a filtered energy
9 spectrum with a peak energy of approximately 160 kVp, compared to the monoenergetic
10 662 keV gamma rays from ^{137}Cs . While a radiation weighting factor of 1 is applied to
11 both gamma rays and x rays for radiation protection purposes (NCRP 1993), the
12 biological effectiveness of low energy photons is approximately twice that of 662 keV
13 ^{137}Cs gamma rays (ICRU 1986). Consequently, a dose of 25 Gy delivered by an x-ray
14 irradiator will not produce the same biological effect as 25 Gy from ^{137}Cs gamma rays.
15 The significance of this difference in radiation effectiveness relevant to transfusion
16 medicine and immunological research is unknown.

17 Regarding costs, the NRC study (2008) quoted about \$180,000 for a new x-ray
18 irradiator and an annual service agreement cost of just over \$10,000. However, the actual
19 cost of the x-ray system has increased. In May 2008 this manufacturer quoted a purchase
20 price of \$250,000 and \$66,000 for a 3-year maintenance contract including a routine
21 service call and one set of replacement parts as needed. While the purchase price might
22 be about the same as a ^{137}Cs irradiator, the annual maintenance cost with a service
23 agreement may be much greater unless the owner has engineering capabilities to provide
24 service and maintenance in-house. Also, the service contract does not include physics
25 services. Depending on the number of set-ups, calibration costs may exceed \$10,000 per
26 year if outside physics services are required. In addition, there would be a one-time cost
27 of installing a 240 volt line to the room for most of the x-ray units replacing a cesium
28 irradiator.

29 Based on repair history of clinical x-ray machines, a user of an x-ray irradiator
30 may experience a higher failure rate and require more service and down-time than a
31 $^{137}\text{CsCl}$ irradiator. Since maintenance of an irradiated blood supply is important,
32 purchasers of x-ray blood irradiators find it necessary to purchase an annual maintenance
33 agreement. However, outside service can result in a facility being unable to perform life-
34 saving irradiations for a time. For example, one owner experienced a service response
35 and re-calibration time of two weeks. Both the upper and lower power supplies had to be
36 replaced after a few years of operation. Therefore, blood banks and hospitals may need
37 to plan for an alternative means of irradiation or an alternative supply of irradiated blood
38 components to meet critical demand. Without $^{137}\text{CsCl}$ as an alternative, the facility may
39 have to purchase two units to assure a continuous supply of irradiated blood.

40 Another factor to evaluate for practicality is the throughput of an x-ray irradiator.
41 Two units of blood can be irradiated at one time with the Raycell, and irradiation time is
42 about 5 min. This is sufficient for two blood centers contacted, which do about 30-100
43 units per month, and it is adequate for a clinic doing about 20 units per day. However, a
44 significant workload like that at a large academic medical center with a throughput of 50-
45 60 units per day may exceed the capabilities of a single x-ray unit. While it may seem
46 that the exposure rate with the x-ray would keep up with the demand, the blood

1 irradiation is not continually as with an assembly line. Rather, units are irradiated as
2 needed based on the clinical demand, in irregular intervals. Thus, the duration required
3 for the irradiation becomes an important limiting factor. One potential buyer stated that
4 about 48,000 blood products could be irradiated within the x-ray tubes' 2000-h warranty
5 period (Blood Bank Talk 2007). For a site processing 50 units per day and assuming that
6 procedures requiring irradiated blood happen mostly during normal work days, that
7 would imply the need for a new tube each 3.7 years, adding considerably to the cost of
8 the operation.

9 Since ^{137}Cs has a half-life of 30 years, it is not financially practical to replace
10 those units that were installed within the last 15 years. Ease of use is comparable
11 between the $^{137}\text{CsCl}$ irradiator and the x-ray irradiator.

12 One issue that has not been investigated is whether all the operating cesium
13 irradiators could afford to replace the units, or whether some facilities will cease
14 operation, depriving patients of irradiated blood and researchers a source of radiation.

15 16 **Biomedical and Small Animal Irradiators**

17
18 Ten x-ray irradiators are commercially available for cell, tissues and small animals, eight
19 from three U.S. manufacturers and two irradiators from outside the U.S. A few will be
20 discussed as being representative of the issues.

21 The **RS 2000** (Rad Source 2007b) has been sold by Rad Source since 1999, with
22 about 15-20 units placed in Europe and Asia and 50-60 placed in the USA. Several users
23 contacted seem satisfied with the device. The purchase price is little over \$100,000, and
24 a service agreement is around \$10,000 per year. Apparently reliability has been good;
25 however, owners should expect to refurbish or replace the power supply about every 4-5
26 years.

27 The Rad Source RS 2400 (Rad Source 2007c), operating between 80 and 160 kV,
28 delivers a higher dose rate using a new technology emitter. This 4-pi x-ray source may
29 have the capability of eventually delivering about 300 Gy min^{-1} , but the two RS 2400s
30 operated considerably lower than this. The International Atomic Energy Agency is
31 testing one of these units for its sterile insect programs. The dose rate and irradiation
32 volume of the RS 2400 are much larger than those for the RS 2000 and may allow five
33 450-ml blood bags to be irradiated simultaneously at a dose rate about 45 Gy min^{-1} .
34 However, the canister loading methodology may need some redesign before it would be
35 practical for irradiation of blood. Rad Source expects to submit its application for FDA
36 approval for irradiation of blood products with this device in 2008. The RS 2400 is
37 expected to sell for about \$200,000 - 250,000 with an annual service contract of about
38 \$20,000. To ensure a high degree of reliability and minimal down time, the service
39 agreement will include a tube replacement every 2000 h.

40 **Faxitron** (2008) sells two irradiation systems, the RX-650 and the CP-160, with
41 prices around \$43,000 and \$87,000 respectively. The Faxitron RX-650 operates at a peak
42 energy of only 130 kVp. To achieve adequate uniformity of dose, Kennedy et al. (2004)
43 had to irradiate the mice from several directions because of the attenuation of the lower
44 energy radiation in the bodies of the mice. Woo and Nordal (2006) concluded that the
45 Faxitron CP-160 could be useful for small animal research if radiation was delivered
46 carefully to ensure accurate and uniform radiation dose. The authors stated that at a

1 distance of 33 cm the indicated beam diameter on the tray was 26 cm, whereas the part of
2 the beam where the uniformity as within 10% was confined to a diameter of 16 cm.

3 **Precision X-Ray Inc.** (2005) sells four different biomedical and small animal x-
4 ray irradiators with energies ranging from 160 kVp to 320 kVp. With 0.5 mm Cu and
5 operating at 320 kV, the unit delivers a dose rate of 2 Gy/minute. The higher tube
6 potential brings the RBE to the same value as the ^{137}Cs gamma ray beam. The price runs
7 around \$170,000, exclusive of the service contract.

8 **Kimtron** markets units similar to the Precision X-ray units, with four units
9 operating between 160 kV and 450 kV. The prices appear comparable to similar units.

10 **Gilardoni**, an Italian company, sells the Radgil (Gilardoni 2000) with an energy
11 of 200 kVp and a dose rate of about 1 Gy min⁻¹ at a cost of about 94,000 Euros
12 (~\$146,000).

13 **Hitachi** (2008) manufactures the MBR-1520-3, which is a 150-kVp blood
14 irradiator that can deliver doses from 15 to 35 Gy in 5-Gy increments. However, there is
15 no indication of FDA approval for human use.

17 **AAPM Survey of Users**

18
19 The American Association of Physicists in Medicine (AAPM) conducted a survey of its
20 members in August to assess their experience with irradiators. The results of the survey
21 would be skewed toward hospital-based or university-based irradiators; however, for the
22 information gathered, that should not affect the conclusions. The survey, since it was
23 targeted at medical physicists and some health physicists, represents only a small part of
24 the irradiators in use. Of the 363 respondents, 297 had irradiators, 84.6% of those used
25 ^{137}Cs as the source, 9.3% used conventional x-ray units and 6% used medical linear
26 accelerators (linacs). The $^{137}\text{CsCl}$ units represented the major vendors. Only 10% were
27 purchased within the last two years, with 7% planning on replacing the units within the
28 next 5 years.

29 A quarter of the $^{137}\text{CsCl}$ units had had some malfunction but most were repaired
30 in less than 7 days. Of the x-ray units, 35% had malfunctions, with 44% being repaired
31 within 7 days.

32 Only 40% of the cesium units were used for blood irradiation, with about 25%
33 used for material irradiations and another 25% for animal irradiations. Of the x-ray units,
34 half were for blood irradiation, while 19% were for material irradiation and 32% for
35 animals. Forty percent of the medical linacs for the respondents were used
36 predominantly for blood irradiation and 11% for animals.

37 This survey indicates that, while fairly reliable, conventional x-ray units and
38 medical linacs account for a small minority of the irradiators in the field. They had
39 slightly more downtime than $^{137}\text{CsCl}$ units. The cesium units have also been reliable and
40 their users, in general, have no plans to replace them. Forced removal of the cesium
41 irradiators would result in a very large loss of resources, both radiation sources and funds,
42 not only for blood banks but research institutions as well.

43

1 **Linear Accelerators**

2
3 Medical linear accelerators (linacs) can and do provide irradiation for blood
4 products and materials. While linacs can serve for animal irradiation, their use with mice
5 presents some difficulties because of the build-up region in the dose that is on the order
6 of the thickness of a mouse. Most facilities that use linacs for irradiation either are part
7 of larger processing facilities (for example, medical product sterilization companies) or
8 find time between patients (creating problems in scheduling and staffing) in a
9 radiotherapy clinic because of the extremely large initial investment, about \$2,000,000
10 for these units and the cost for maintenance of \$200,000 per year. Night time irradiations
11 pose additional staffing issues. Because of the costs, linacs are not a viable replacement
12 for ¹³⁷CsCl irradiators for the vast majority of facilities.

13
14 **Alternative Radionuclides**

15
16 At the time of writing, the only reasonable alternative radionuclide source for
17 irradiators would be ⁶⁰Co. This radionuclide is used in large industrial irradiators, but is
18 not currently available for blood or research irradiators. The use of ⁶⁰Co would require
19 frequent source change due to the much shorter half-life compared with ¹³⁷Cs (5.27 years
20 compared with 30 years), and higher initial source activities to extend the useful life of
21 the sources. The ⁶⁰Co also requires thicker shielding because of the higher energy (1.2
22 cm half-value layer in lead compared with 0.6 cm.) Since the half-value layer enters into
23 shielding as an exponent, the difference in the thickness of shield required due to the
24 differences in the values multiples rapidly. These two considerations would lead to high
25 initial costs for a unit and frequent, repetitive costs for source replacement. Finally, there
26 is no convincing evidence that the ⁶⁰Co sources of any form would pose less of a hazard
27 than the ¹³⁷CsCl.

28
29 **Further Considerations for Blood Irradiation**

30
31 The subcommittee consulted 10 hematologists or oncologists and one clinical laboratory
32 director. These included researchers at one of the nation's most prestigious blood
33 disorder and hematologic cancer research centers having extensive use of ¹³⁷CsCl blood
34 and small animal irradiators.

35 Most of the previous information, such as in the National Research Council
36 report, focused use of irradiators at central blood banks.

37 Five of the 10 hematologists/oncologists reported that they regularly prescribe
38 irradiated blood for transfusions. Of these, one said that up to 40% of all blood he
39 prescribed was irradiated. The others estimated that 15% to 33% of all blood for
40 transfusion was irradiated. They all mentioned that their patient population was the
41 reason why they tended to prescribe more irradiated blood products than the nominal
42 10% that often is used for planning. Patients who are post transplant are one such
43 category, although none of these physicians had many patients in this subset. The more
44 common reason was the use of certain chemotherapeutics that severely affect the host
45 immune system.

- 1 11. Use trusted carriers with package tracking systems, who maintain constant control
2 during transit, and who maintain communication for response or assistance.
- 3 12. Notify the NRC 90 days prior to certain shipments.

4 To review the changes resulting from the NRC orders for increased controls, a site
5 visit for one of the members of this subcommittee was arranged to a major medical center
6 with four ¹³⁷CsCl blood irradiators. The visit found that the licensee maintained access
7 control to the irradiators by the means required in the Order, including:

- 8 1. Allowing access only to approved personnel who had undergone a thorough FBI
9 background check, fingerprinting, work history review, psychological review, and
10 local law enforcement background check.
- 11 2. Allowing access only to persons needing and trained to use the irradiators properly.
- 12 3. Providing redundant enforced doors, locks, heavy walls, computer-coded key-card
13 access, and continuous video monitoring of the halls, entry, and workspace occupied
14 by the irradiator units.
- 15 4. Presenting documented procedures to ensure that authorized users support the
16 institutions system to prevent unauthorized access and protect access information,
17 drawings, schematics, maps, and facility floor plans from unauthorized use.
- 18 5. Coordinating with local law enforcement agencies for rapid response to any
19 attempted intrusion or theft of radioactive material.

20 In addition, we found the irradiator systems to be outfitted with additional
21 padlocks and security measures for preventing unauthorized access to radioactive sources
22 inside the irradiators. The irradiators weigh 4000 to 5000 pounds and do not have
23 wheels.

24 In summary, we found highly increased security of ¹³⁷CsCl irradiators and
25 increased controls over access by authorized personnel at the institution. It would be
26 very difficult, even for personnel with access permission, to attempt theft, diversion, or
27 misuse of the ¹³⁷CsCl irradiator systems. The institution had implemented all
28 requirements to enhance the security of ¹³⁷CsCl irradiator systems in a manner typical of
29 such irradiators.

30 In addition to the increased security enhancements required by the NRC, an
31 initiative by the Department of Energy (DOE), the Department of Homeland Security
32 (DHS), and the Domestic Nuclear Detection Office will harden ¹³⁷CsCl irradiators
33 throughout the United States to delay unauthorized access to ¹³⁷Cs sources. This has
34 been a cooperative effort for the past 18 months. The demonstration project was
35 completed in March of 2008 and the pilot project is currently being conducted in nine
36 facilities. DOE and DHS anticipate that this pilot program will be completed later this
37 year.

38 The pilot project is the actual enhancement of the irradiators in the field. The
39 manufacturer will install additional material and make minor changes to the exterior of
40 the irradiator to make it more difficult to remove the source(s). There are nine facilities
41 that have volunteered to participate. The pilot will have two of the manufacturers visit
42 the facility and add the enhancements to the irradiators. The pilot will demonstrate the
43 ease and ability of performing these tasks in a “real world” environment. The pilot will
44 also validate the costs to perform the retrofit. It is estimated that the cost will be \$2,000
45 to 4,000 for each device. The DHS and the DOE will pay the manufacturers for the

1 enhancements. It is expected that the pilot will be successful and the project will be open
2 to all of the devices currently licensed in the United States.

3 4 **Alternative Forms for ¹³⁷Cesium Sources**

5
6 The subcommittee considered whether this report should recommend to
7 manufacturers of ¹³⁷CsCl irradiators that alternatives to the powder form of the source be
8 pursued. However, as of this time, there is no convincing evidence that another form,
9 particularly a solid form, would be safer. While a powder may be dispersed by a bomb, a
10 solid poses a radiation hazard much greater than the dispersed powder. In addition, the
11 manufacture of a solid source could pose a hazard to the workers making the sources.

12 13 **Conclusions**

- 14
- 15 1. Cesium-137 irradiators are used in a number of important medical and research
16 applications. As the population of the United States ages, the use of irradiated
17 blood products will escalate, producing an increased demand for the availability
18 of this technology for patient safety. The need for medical irradiators is
19 unquestionable.
 - 20 2. Some investigators are concerned about the ways that differences in radiation
21 quality between ¹³⁷CsCl irradiators and x-ray systems would affect experimental
22 results on blood samples, small animals, separated T-cells and stem cells, and
23 other biological media.
 - 24 3. Alternatives to ¹³⁷CsCl irradiators are expensive, and forcing the switch to x-ray
25 sources would place an unnecessary and great financial burden on blood banks
26 and research institutions.
 - 27 4. The ACMUI subcommittee believes that the ¹³⁷Cesium Chloride Irradiator
28 Security Enhancements and Increased Controls and Security Inspections have
29 provided strong measures for ensuring the safety and integrity of ¹³⁷CsCl sources
30 in medical irradiators, have reduced the vulnerability of these devices as material
31 suitable for malicious intent, and should prove to be acceptable as an alternative
32 to removal or prohibition of these devices.

33 34 **ACMUI ¹³⁷CsCl Irradiator Subcommittee**

35
36 Debbie Gilley^{1,2}
37 Darrell Fisher^{3,4} (Lead of the Security Subgroup)
38 Ralph Lieto²
39 Orhan Suleiman^{2,3}
40 Bruce Thomadsen² (Chair)
41 Richard Vetter¹ (Lead of the X-ray Alternative Subgroup)
42 James Welsh³ (Lead of the Need Subgroup)
43 ¹Member, X-ray Alternative Subgroup
44 ²Member, Security Subgroup
45 ³Member, Need Subgroup
46

REFERENCES

- 1
2
3 Best Theratronics Ltd. Product overview-Raycell. Ottawa: Best Theratronics Ltd.;
4 2008. Available at: http://www.theratronics.ca/product_raycell.html . Accessed 12 May
5 2008.
6
7 Blood Bank Talk. Moving from Cesium-137 Blood Irradiators to X-ray Blood
8 Irradiators. Blood Bank Talk; 2007. Available at:
9 <http://www.bloodbanktalk.com/forum/>. Accessed 14 May 2008.
10
11 Faxitron X-ray LLC. RX-650 and CP-160 irradiator systems. X-ray LLC; 2008.
12 Available at: <http://www.faxitron.com/products/rx650-cp160.html>. Accessed 14 May
13 2008.
14
15 Gilardoni. RADGIL X-ray Treatment Unit. Gilardoni; 2000. Available at;
16 <http://www.gilardoni.it/pdf/radgil.pdf> . Accessed 14 May 2008.
17
18 Hitachi Medical Systems. 2008.
19 <http://hitachimedicalsystems.com/product/xirr/mbr1520a3.html>
20
21 International Commission on Radiation Units and Measurements. The quality factor in
22 radiation protection. Bethesda, MD: ICRU; ICRU Report 40; 1986
23
24 Janatpour, R., et al., Comparison of X-ray vs. gamma irradiation of CPDA-1 red cells,
25 Vox Sang 89: 215-219; 2005.
26
27 Kennedy PJ, Wang L, Burke MJ, Sullivan G, Hernandez JM, Tse WT. Irradiation
28 Conditions Necessary for Murine Bone Marrow Ablation Utilizing an X-Ray-Based
29 Irradiator [Abstract]. Blood 104 (Suppl 1): 321b; 2004.
30
31 National Council on Radiation Protection and Measurements. Limitation of exposure to
32 ionizing radiation. Bethesda, MD: NCRP; NCRP Report No. 116; 1993
33
34 National Research Council, Radiation Source Use and Replacement. Washington, DC:
35 The National Academies Press; 2008.
36
37 Precision X-ray, Inc. X-RAD X-Ray Irradiators. North Branford: Precision X-ray Inc;
38 2005. Available at: <http://www.pxinc.com/xrad.html>. Accessed 17 May 2008.
39
40 Rad Source Technologies, Inc. Irradiation without Radioactive Isotopes. Alpharetta:
41 Rad Source Technologies, Inc; 2007a, Available at: <http://www.radsources.com> .
42 Accessed 12 May 2008.
43
44 Rad Source Technologies, Inc. Irradiation without Radioactive Isotopes. Alpharetta:
45 Rad Source Technologies, Inc; 2007b, Available at:
46 http://www.radsources.com/irradiation_rs2000.html . Accessed 12 May 2008.

1
2 Rad Source Technologies, Inc. Irradiation without Radioactive Isotopes. Alpharetta:
3 Rad Source Technologies, Inc; 2007c, Available at:
4 http://www.radsources.com/irradiation_rs2400.html . Accessed 12 May 2008.
5
6 Woo, M.K., Nordal, R.A., Commissioning and evaluation of a new commercial small
7 rodent x-ray irradiator, Biomed Imaging Interv J 2: e10; 2006.
